Pembrolizumab (Keytruda®). HTA ID: 23070

Assessment Status Rapid Review Complete
HTA ID 23070
Drug Pembrolizumab
Brand Keytruda®
Indication Pembrolizumab (Keytruda®) is indicated in combination with fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced, unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1
Assessment Process
Rapid review commissioned 21/11/2023
Rapid review completed 18/12/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.